- Dec 13, 2002
NCT00048230: Phase 3 - PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With RRMM
Phase 3 - PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma NCT00048230 This study will compare the efficacy of PS-341 versus high dose dexamethasone. Sponsor: Millennium Pharmaceuticals, Inc. Multiple locations International Study ClinicalTrials.gov Identifier: NCT00048230 Official Title: An International, Multi-Center, Randomized, Open-Label Study of PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Rel
125
- Dec 8, 2002
IFM 9502 trial: 200 mg/m(2) melphalan Vs 8 Gy TBI + 140 mg/m(2) melphalan as conditioning Blood 2002
(Intergroupe Francophone du Myélome [IFM] 9502 trial) Time Frame: July 1995 to January 1999 IFM 9502 trial: 200 mg/m(2) melphalan Vs 8 Gy TBI + 140 mg/m(2) melphalan as conditioning Blood 2002 Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 random
23